SUPPLEMENTARY INFORMATION:

In a document published in the Federal Register on January 25, 2023 (88 FR 4826), Mark Moffett was permanently debarred from providing services in any capacity to a person with an approved or pending drug product application under sections 505, 512, or 802 of the FD&C Act (21 U.S.C. 355, 360b, or 382), or under section 351 of the Public Health Service Act (42 U.S.C. 262). The debarment was based on FDA's finding, under section 306(a)(2)(B) of the FD&C Act (21 U.S.C. 335a(a)(2)(B)), that Mr. Moffett had been convicted of a felony under Federal law for conduct relating to the regulation of any drug product.

Mr. Moffett appealed the judgment of the District Court, and on November 18, 2022, the U.S. Court of Appeals for the First Circuit issued a judgment vacating Mr. Moffett's convictions as to all counts. On January 26, 2023, Mr. Moffett petitioned FDA for withdrawal of his debarment, citing section 306(d)(3)(B)(i) of the FD&C Act. Pursuant to section 306(d)(3)(B)(i) of the FD&C Act, “If the conviction which served as the basis for the debarment of an individual under subsection (a)(2) . . . is reversed, the Secretary shall withdraw the order of debarment.”

FDA has concluded that because the U.S. Court of Appeals for the First Circuit vacated Mr. Moffett's convictions, the order of debarment must be withdrawn. Accordingly, the Assistant Commissioner, Office of Human and Animal Food Operations, under section 306(d)(3)(B)(i) of the FD&C Act, under authority delegated to the Assistant Commissioner, is issuing this order withdrawing the order that permanently debarred Mark Moffett from providing services in any capacity to a person with an approved or pending drug product application.

88 FR 45228